Tenofovir Abacavir Platelet Activation Study (TAPAS)
Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Copenhagen
-
Copenhagen Ø, Copenhagen, Denmark, 2100
- Rigshospitalet, Klinik for Infektionsmedicin og Reumatologi, 8622
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infected
- Can understand and sign written informed consent
- Received one of the above mentioned antiretroviral regimens continuously ≥ 6 months
- HIV RNA < 400 copies/mL for ≥ 6 months
Exclusion Criteria:
- Receiving anticoagulant therapy, adenosine diphosphate (ADP) receptor inhibitors, aspirin or nonsteroidal antiinflammatory drugs (NSAIDs)
- Previous ischemic heart disease, peripheral atherosclerotic disease or stroke
- Coagulation disorder (e.g. hemophilia, factor V Leiden mutation)
- Platelet count < 150 x 109/L during the past 6 months from inclusion
- Estimated glomerular filtration rate (eGFR) <70 during the past 6 months from inclusion
- Humane leukocyte antigen (HLA)-B*57:01 positive genotype
- Hepatitis B or C positive during the past year from inclusion
- Hypersensitivity to the active substances or to any of the excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tenofovir to abacavir
Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
|
|
|
Experimental: Abacavir to tenofovir
Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Differences in platelet aggregation (Multiplate) before and after switching between abacavir and tenofovir.
Time Frame: before and after 90 days intervention
|
before and after 90 days intervention
|
|
Differences in clot formation kinetics (thromboelastography) before and after switching between abacavir and tenofovir.
Time Frame: before and after 90 days intervention
|
before and after 90 days intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Concentration of plasma lipids
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
activated partial thromboplastin time (APTT)
Time Frame: 90 days
|
90 days
|
|
international normalized ratio (INR)/Factor II, VII, X
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Platelet count
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Fibrinogen
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
D-dimer
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Antithrombine
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Interleukin 6 (IL-6)
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
High sensitivity C reactive protein (HS-CRP)
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Soluble P-Selectin
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
soluble CD40 ligand (sCD40L)
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Syndecan-1
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Soluble E-selectin
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
|
Tissue plasminogen activator
Time Frame: Before and after 90 days intervention
|
Before and after 90 days intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jan Gerstoft, MD, DMSc, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013-001685-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.